On May 13, 2024 Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, reported that five abstracts have been accepted for presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting being held June 8 – 11, 2024, in Toronto, Canada (Press release, Actinium Pharmaceuticals, MAY 13, 2024, View Source [SID1234643126]). The abstracts will feature results from the Phase 3 SIERRA trial of Iomab-B, a CD45 targeting ARC with the Iodine-131 payload, intended for conditioning to prepare patients for a potentially curative bone marrow transplant (BMT) and results from a Phase 1b trial of Actimab-A, a CD33 targeting ARC with the Actinium-225 payload, in combination with the chemotherapy regimen CLAG-M. Iomab-B and Actimab-A are the only targeted radiotherapies in development for patients with relapsed/refractory acute myeloid leukemia (r/r AML), a blood cancer that is highly sensitive to radiation. In addition, an abstract detailing proprietary linker technology applicable for solid tumor targeting ARCs developed by Actinium will be presented for the first time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sandesh Seth, Actinium’s Chairman and CEO, said, "Our presence at this year’s SNMMI showcases the breadth of Actinium’s capabilities and leadership in the development of Antibody Radiation Conjugates. We look forward to highlighting the potential for targeted radiotherapy in blood cancers to the nuclear medicine community, which represents a significant expansion opportunity for the field. The data from Iomab-B and Actimab-A that will be presented at SNMMI demonstrate the potential of targeted radiation to treat patients with high-risk, difficult-to-treat r/r AML, including the ability overcome mutations such as TP53 and those who have had extensive prior therapies."

Actinium’s SNMMI presentations are detailed below:

Safety and Dosimetric Analysis of Lintuzumab-Ac225 in Combination with Intensive CLAG-M Chemotherapy in Patients with Relapsed/Refractory AML

Exploratory Analysis of Bone Marrow Dosimetry from the Randomized Phase 3 SIERRA Trial of Iomab-B (131I-apamistamab) Prior to HCT in Relapsed/Refractory Acute Myeloid Leukemia

Survival Outcomes and Dosimetric Analysis of Iomab-B (131I-apamistamab) Followed by Allogeneic Hematopoietic Cell Transplant for Patients with TP53 Mutated Relapsed/Refractory AML

Mathematical Modeling of Exposure Measurements Following High-Dose Targeted Therapy Using 131I-apamistamab: Analysis From the Large Multicenter Phase III SIERRA Trial

Evaluation of novel DOTA-based linkers for improved targeted radiotherapy delivery to solid tumors

About the SNMMI Annual Meeting

The SNMMI Annual Meeting is recognized as the premier educational, scientific, research, and networking event in nuclear medicine and molecular imaging. The four-day event, taking place each June, provides physicians, technologists, pharmacists, laboratory professionals, and scientists with an in-depth view of the latest research and development in the field as well as providing insights into practical applications for the clinic.